Cargando…

Quality of Sarcoma Care: Longitudinal Real-Time Assessment and Evidence Analytics of Quality Indicators

SIMPLE SUMMARY: This article comprehensively defines, assesses and analyzes quality indicators of sarcoma care. A novel interoperable digital platform is presented that gathers information from physicians (work-up, therapy and MDT information) as well as patients (PROMS/PREMS) consecutively and inst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heesen, Philip, Studer, Gabriela, Bode, Beata, Windegger, Hubi, Staeheli, Benjamin, Aliu, Paul, Martin-Broto, Javier, Gronchi, Alessandro, Blay, Jean-Yves, Le Cesne, Axel, Fuchs, Bruno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817921/ https://www.ncbi.nlm.nih.gov/pubmed/36612043 http://dx.doi.org/10.3390/cancers15010047

Ejemplares similares

The Next Frontier in Sarcoma Care: Digital Health, AI, and the Quest for Precision Medicine
por: Fuchs, Bruno, et al.
Publicado: (2023)

The Sarcoma-Specific Instrument to Longitudinally Assess Health-Related Outcomes of the Routine Care Cycle
por: Mosku, Nasian, et al.
Publicado: (2023)

Enhancing Healthcare for Sarcoma Patients: Lessons from a Diagnostic Pathway Efficiency Analysis
por: Elyes, Maria, et al.
Publicado: (2023)

Biopsy Ratio of Suspected to Confirmed Sarcoma Diagnosis
por: Mosku, Nasian, et al.
Publicado: (2022)

Unlocking the Power of Benchmarking: Real-World-Time Data Analysis for Enhanced Sarcoma Patient Outcomes
por: Fuchs, Bruno, et al.
Publicado: (2023)

Time and Accuracy to Establish the Diagnosis of Soft Tissue Tumors: A Comparative Analysis from the Swiss Sarcoma Network
por: Wellauer, Hanna, et al.
Publicado: (2022)

Pregnancy in Women with Metastatic Sarcomas
por: Yazigi, Alexandre, et al.
Publicado: (2020)

Surrogate endpoints in advanced sarcoma trials: a meta-analysis
por: Savina, Marion, et al.
Publicado: (2018)

Harmonization of pre-analytical quality indicators
por: Plebani, Mario, et al.
Publicado: (2014)

Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG)
por: Lindner, Lars H., et al.
Publicado: (2018)

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
por: Bertucci, François, et al.
Publicado: (2019)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study
por: Brodowicz, Thomas, et al.
Publicado: (2020)

Immunologic constant of rejection signature is prognostic in soft-tissue sarcoma and refines the CINSARC signature
por: Bertucci, Francois, et al.
Publicado: (2022)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015)

Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network
por: Sanfilippo, Roberta, et al.
Publicado: (2015)

CSPG4 expression in soft tissue sarcomas is associated with poor prognosis and low cytotoxic immune response
por: Boudin, Laurys, et al.
Publicado: (2022)

Quality of Life and Utility in Patients with Metastatic Soft Tissue and Bone Sarcoma: The Sarcoma Treatment and Burden of Illness in North America and Europe (SABINE) Study
por: Reichardt, Peter, et al.
Publicado: (2012)

Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups
por: Gronchi, Alessandro, et al.
Publicado: (2019)

How Is the Spectrum of Sarcoma Surgery Assessed?
por: Theus-Steinmann, Carlo, et al.
Publicado: (2023)

French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak
por: Penel, N., et al.
Publicado: (2020)

Staging Systems and Nomograms for Soft Tissue Sarcoma
por: Danieli, Maria, et al.
Publicado: (2023)

Metabolic landscapes in sarcomas
por: Miallot, Richard, et al.
Publicado: (2021)

Molecular Mechanisms of Kaposi Sarcoma Development
por: Karabajakian, Andy, et al.
Publicado: (2022)

TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021)

Evaluation of four quality indicators of the Pre-Analytical Phase External Quality Assessment Subprogram of the Fundación Bioquímica Argentina
por: Unger, Gisela, et al.
Publicado: (2023)

Metabolite Ratios as Quality Indicators for Pre-Analytical Variation in Serum and EDTA Plasma
por: Heiling, Sven, et al.
Publicado: (2021)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

Sarcoma nomograms: a light over the darkness
por: Callegaro, Dario, et al.
Publicado: (2017)

Synovial sarcoma: characteristics, challenges, and evolving therapeutic strategies
por: Blay, J.-Y., et al.
Publicado: (2023)

Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
por: Patrikidou, Anna, et al.
Publicado: (2020)

The off-label use of targeted therapies in sarcomas: the OUTC’S program
por: Eberst, Lauriane, et al.
Publicado: (2014)

INdAM Workshop on Analytic Aspects of Convexity
por: Bianchi, Gabriele, et al.
Publicado: (2018)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward
por: Istl, Alexandra C., et al.
Publicado: (2022)

Pharmacogenetic Study of Trabectedin-Induced Severe Hepatotoxicity in Patients with Advanced Soft Tissue Sarcoma
por: Maillard, Maud, et al.
Publicado: (2020)

Quality in the analytical chemistry laboratory /
Publicado: (1995)

Trabectedin and its potential in the treatment of soft tissue sarcoma
por: Cassier, Philippe A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_boi7i5dkv9ds4gmq88b5bqfaat